kidney disease and semaglutide in Diabetic Disease: Integrating Clinical Evidence with Mechanistic Insights Semaglutide lowers UACR in overweight

If you experience serious side effects, seek medical advice from your doctor before taking the next dosage

[5] Some patients with obesity may have mild elevations in cortisol or altered cortisol metabolism related to their weight status, and substantial weight loss could potentially normalise these patterns, though evidence for this specific effect is limited

A 2024 study in the Journal of Clinical Oncology reported that GLP-1 drugs helped women with early-stage breast cancer and overweight or obesity achieve significant weight loss

Originally developed for type 2 diabetes, semaglutide is now frequently used for weight management because of its ability to regulate appetite and blood sugar